Company Tissue Repair Ltd

Tissue Repair Limited is an Australia-based Phase 3 advanced biotechnology company developing second generation wound healing agents. The Company's core focus is entering Phase 3 clinical trials in chronic wounds for its lead drug candidate TR987, with a secondary focus on commercializing TR Pro+ a post procedure topical gel to accelerate healing and improve skin quality following cosmetic and medical procedures. Its TR Pro+ product provides a range of benefits that assists damaged skin to heal and maintains skin hydration for a moist healing environment to encourage normal scar formation. The Company is also focused on commercializing its propriety Glucoprime active pharmaceutical ingredient (API) to treat a variety of wounds and skin conditions. Glucoprime is a β-glucan molecule, which is designed to assist skin healing and is delivered topically in a hydrogel formulation.